NDA 011366 · Xeris
Keveyis
Dichlorphenamide · Oral · Carbonic Anhydrase Inhibitor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Nov 22, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1958
Jul 22, 1958
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2
2 Phase 3, 0 recruiting
FAERS reports
1,646
461 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 4, 2026.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants ( 1 )
Mechanism: Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 22, 2019 Supplement 33 · Efficacy OrphanLetterLabel
- Aug 7, 2015 Supplement 30 · Efficacy · priority review OrphanLetterLabel
- Jul 22, 1958 Original approval · Type 1 - New Molecular Entity
2 products under this application
- KEVEYIS · DICHLORPHENAMIDE 50MG · TABLET, ORAL · Prescription · TE AB
- DARANIDE · DICHLORPHENAMIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Dichlorphenamide" as an intervention, any sponsor and status, largest first.
- Hyper- and Hypokalemic Periodic Paralysis StudyPivotal-lookingCompleted
University of RochesterAcademic, hospital or other
NCT00494507 · 71 participants · Start Jun 2007 · Primary completion Apr 2013
Drug: Dichlorphenamide (double-blind); Placebo (double-blind) and 1 more · For: Hyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis
Sites: Los Angeles, California; San Francisco, California; Kansas City, Kansas · 12 sites in all
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel DisordersPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00004802 · 64 participants · Start Jun 1992
Drug: dichlorphenamide · For: Paralysis, Hyperkalemic Periodic; Hypokalemic Periodic Paralysis; Paramyotonia Congenita
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- paraesthesia304
- fatigue231
- disease recurrence173
- muscular weakness165
- feeling abnormal162
- wrong technique in product usage process151
- asthenia145
- confusional state129
- dizziness119
- nausea117
- headache102
- blood potassium decreased97
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2015 | 9 |
| 2016 | 37 |
| 2017 | 158 |
| 2018 | 313 |
| 2019 | 261 |
| 2020 | 295 |
| 2021 | 348 |
| 2022 | 33 |
| 2023 | 38 |
| 2024 | 63 |
| 2025 | 55 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Keveyis (Dichlorphenamide)
2024 spending
$23.5M
Beneficiaries
111
838 claims
Per beneficiary
$211,771
$374.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $354,402 |
| 2023 | $20,667,743 |
| 2024 | $23,506,537 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Patient tolerance to carbonic anhydrase inhibitors.
Lichter PR, Newman LP, Wheeler NC, et al. · Am J Ophthalmol 1978 · Clinical Trial, Comparative Study
- Treatment for periodic paralysis.
Sansone V, Meola G, Links TP, et al. · Cochrane Database Syst Rev 2008 · Systematic Review
- Safety and efficacy of dichlorphenamide in patients with periodic paralysis: A systematic review and meta-analysis.
Haider S, Siddiqui AD, Asad M, et al. · Neuromuscul Disord 2026 · Systematic Review, Meta-Analysis
- Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.
Sansone VA, Burge J, McDermott MP, et al. · Neurology 2016 · Multicenter Study, Randomized Controlled Trial
- [Dichlorphenamide treatment in acute glaucoma (author's transl)].
Bleckmann H · Albrecht Von Graefes Arch Klin Exp Ophthalmol 1976 · Clinical Trial, Comparative Study
- Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers.
Cohen F · Clin Pharmacol Drug Dev 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Xeris · Also marketed as Daranide
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.